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Intellectual Property and Access to Essential
Pharmaceuticals: Recent Law and Policy
Reforms in the Southern Africa Development
Community Region
CHIKOSA BANDA†

I. INTRODUCTION: BACKGROUND AND CONTEXT
The advent of the 1994 Agreement on Trade Related Aspects of
Intellectual Property Rights (TRIPS)1 has given rise to an
unprecedented and polarized debate concerning the impact of
intellectual property rights (IPRs) on access to essential
pharmaceuticals. This debate has focused on the patent system and the
role it plays in determining the affordability and accessibility of
pharmaceuticals, especially in developing countries. The debate has
largely been between those who contend that patents adversely affect
access to essential pharmaceuticals and those who claim that patents
are necessary and essential for the promotion of biomedical research
© 2016 Chikosa Banda.
† LLM, LLB Faculty of Law, University of Malawi Chancellor College of Law. I would
like to acknowledge and thank Professors Lionel Bently and Dr. Kathleen Liddell of the
University of Cambridge for supervising my doctoral research, and the Wellcome Trust who
funded my research. I would also like to acknowledge Dr. Wilbert Bannenberg from HERA,
whom I have worked with on SADC IP issues, and thank Professor Peter Danchin and the
University of Maryland Carey School of Law for inviting me to participate and collaborate on
the symposium Roundtable on Clinical Trials and Access to Essential Medicines in African
Countries that took place on Oct. 29-30, 2015. Additionally, I would like to thank the editorial
staff of the Maryland Journal of International Law for their editorial assistance and hard work
on this piece. Finally, I would also like to acknowledge my wife Tiffany and children,
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* The Editors and the Maryland Journal of International Law thank the author for his
contribution to Volume 31 and note that author is solely responsibility for the content and
accuracy of references published. 1. Agreement on Trade-Related Aspects of Intellectual
Property Rights, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade
Organization, Annex 1C, 1869 U.N.T.S. 299 [hereinafter TRIPS Agreement].
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and development (R&D).
This article contributes to this debate by outlining the flexibilities
the TRIPS Agreement offers to developing and least developed
countries (LDCs). It exposes a major weakness of the dominant
debates surrounding the issue of intellectual property and access to
medicines in the Southern African Development Community (SADC)
region and offers a proposal to minimize the international dependence
on India’s generic medication production. This article argues that the
current approaches to the reform of patent law in the SADC are
reductive in as far as they assume that the problem of access to
pharmaceuticals can be resolved by merely implementing TRIPS
flexibilities to facilitate the importation of pharmaceuticals from India,
currently the world’s largest generic manufacturer for developing
countries. It contends that addressing the problem of access to
medicines requires more holistic and sustainable solutions, including
taking advantage of the decision of the World Trade Organization
(WTO) General Council on Paragraph 6 of the Doha Declaration on
the TRIPS Agreement and Public Health (30 August WTO Decision)
to stimulate local/regional production of pharmaceuticals.
This paper has six parts. Part I sets out the background and
context of this paper. It argues that reforms aimed at taking full
advantage of TRIPS flexibilities to import pharmaceutical products
represent short- and medium-term solutions to existing access to
medicines problems and are unlikely to provide satisfactory and
sustainable long-term solutions. Even though Member States
predominantly rely on imported generic medicines for their healthcare
needs, “there is a need for local production of medicines as reliance on
imports may not be sustainable for these countries.”2
Part II considers the current situation of innovation and access to
medicines in the SADC region. It also outlines the major barriers to
innovation and access in the SADC. The section contends that the
challenges of pharmaceutical innovation and access in the SADC are
multiple and multifaceted, and accordingly, they require regional and
even global solutions to surmount. Part III discusses the SADC
regional level policy reforms aimed at harnessing economies of scale
to stimulate local/regional production of pharmaceuticals. This part
argues that the fact that most SADC Members States are LDC is
potentially beneficial to the SADC since individual Member states can
2. Nirmalya Syam, Transition Period for LDCs: Implications for Local Production of
Medicines in the East African Community, RESEARCH PAPERS 59: THE SOUTH CENTRE, 2
(2014).
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take advantage of the waivers provided for in the 30 August WTO
Decision to produce generic pharmaceuticals for export within the
region.
Part IV highlights recent domestic level reforms to incorporate
TRIPS flexibilities. The major observation in this section is that most
countries in the SADC region have initiated reforms aimed at
domesticating TRIPS flexibilities. However, this part notes that the
pace at which these reforms are taking place indicates that these
countries do not consider these reforms a major priority in their
national legal and policy environment. This may pose problems for
local/regional production.
Part V outlines the challenges that SADC Members face in
implementing TRIPS flexibilities. The major challenge highlighted in
this part is the incoherence between national and regional level policies
and between national level policies. This part argues that it would be
difficult to make progress towards the realization of the right to access
pharmaceuticals by addressing these incoherencies. Part VI is the
Conclusion.
A. TRIPS and Access to Pharmaceuticals
Global efforts to address TRIPS-related public health concerns
subsequently led to the adoption of the Declaration on TRIPS and
Public Health (the “Doha Declaration”) by a WTO Ministerial
Conference held in 2001.3 The Doha Declaration reaffirmed that the
TRIPS Agreement should be “interpreted in a manner that is
supportive of WTO Members’ right to protect public health and, in
particular, to promote access to medicines for all.”4 It also reaffirmed
the right of states to authorize manufacturers to copy patented
inventions without the permission of the patent holder during “national
emergencies or circumstances of extreme urgency.”5 This may include
the use of devices such as compulsory licensing. Compulsory licensing
refers to the “state-authorized licensing of generic medicines to be
produced or bought without the patent owners consent, even though
this derogates from the brand-name drug’s market exclusivity.”6
3. Doha WTO Ministerial Declaration on the TRIPS and Public Health
[WT/MIN(01)/DEC/220
November
2001],
https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm (last accessed
Dec. 8, 2016) [hereinafter Doha Declaration].
4. Id. para. 4.
5. Id.
6. Reed F. Beall, Randal Kuhn, & Amir Attaran, Compulsory Licensing Often Did Not
Produce Lower Prices for Antiretrovirals Compared to International Procurement, 34
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Paragraph 7 of the Declaration exempts LDCs from TRIPS compliance
with respect to pharmaceutical products until 1 January 2016.7 This
period has since been extended to 1 January 2033 by the decision of
the Council for TRIPS of 6 November 2015.8 Paragraph 6 of the Doha
Declaration recognizes the fact that some WTO Members have limited
or no pharmaceutical manufacturing capacity. Consequently, they
could face difficulties “in making effective use of compulsory
licensing under the TRIPS Agreement.”9 This is because Article 31 of
the TRIPS Agreement severely restricts the freedom of States to use
compulsory licenses. The Article provides that a government may only
authorize use of the subject matter of a patent without the consent of
the right-holder where such use is “predominantly for the supply of the
domestic market of the member authorizing such use.”10 Countries
with insufficient or no manufacturing capacity may not take full
advantage of compulsory licensing due to their dependence on external
manufacturers for their domestic needs. The Ministerial Conference,
accordingly, instructed “the Council for TRIPS to find an expeditious
solution to this problem.”11
Pursuant to the above instruction, the General Council of the
TRIPS subsequently adopted a decision to make it easier for states with
insufficient manufacturing capacity to import generic medicine in the
event of a public health crisis. The decision, adopted on 30 August
2003, waived the application of Article 31 of the TRIPS Agreement in
favor of countries with insufficient or no manufacturing capacity. It
made it permissible for Members to grant compulsory licenses for
exportation of pharmaceutical products to Members with insufficient
or no manufacturing capacity.12 Paragraph 6 of the decision further
HEALTH AFF. 493 (2015).
7. The paragraph states:
We also agree that the least-developed country Members will not be obliged,
with respect to pharmaceutical products, to implement or apply Sections 5 and 7
of Part II of the TRIPS Agreement or to enforce rights provided for under these
Sections until 1 January 2016, without prejudice to the right of least-developed
country Members to seek other extensions of the transition periods as provided
for in Article 66.1 of the TRIPS Agreement.
Doha Declaration at para. 7. This was formalized by a subsequent decision by
the TRIPS Council of 27 June 2002.
8. Council for Trade-Related Aspects of Intellectual Property Rights, Extension of the
Transition Period under Article 66.1 of the TRIPS Agreement for Least Developed Country
Members for Certain Obligations with Respect to Pharmaceutical Products (Decision of the
Council for TRIPS of 6 November 2015- IP/C/73).
9. See Doha Declaration, supra note 3, para. 6.
10. TRIPS Agreement, supra note 1 Article 31(h).
11. Doha Declaration, supra note 3, para. 6.
12. Paragraph 1(b) of the Decision on the Implementation of Paragraph 6 of the TRIPS
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waives the requirements of Article 31(f) of the TRIPS Agreement in
order to facilitate the local production of pharmaceuticals by “a party
to a regional trade agreement within the meaning of Article XXIV of
the GATT” for exportation to members of a regional trade agreement
with insufficient or no manufacturing capacity.13 In December 2005,
the WTO Members adopted a protocol to amend the TRIPS Agreement
to formalize the decision of 30 August 2003.14 The amendment, known
as Article 31bis of the TRIPS, entered into force on 23 January 2017,
upon ratification by two-thirds of the WTO Members.15
In addition, LDCs are exempt from implementing the general
provisions of the TRIPS save for Articles 3, 4, and 5 until 1 July 2021.16
They are also exempt from implementing, protecting, and enforcing
patents on pharmaceuticals until 1 January 2033.17 The waiver is in line
with article 66 of the TRIPS Agreement, which recognizes the “the
special needs and requirements of least-developed country Members,
their economic, financial and administrative constraints, and their need
for flexibility to create a viable technological base.”18 The exemption
was for an initial period of ten years.19 This period was made subject
to extension upon a duly motivated request by an LDC.20

and Public Health Agreement.
13. Id.
14. World Trade Organization General Council Decision of 6 December of 2006,
Amendment of the TRIPS Agreement , Decision Of The General Council , WT/L/641
(December 6, 2005), https://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm.
15. WTO, WTO IP Rules Amended to Ease Poor Countries Access to Affordable
Medicines
,
2017
News
Items
,
23
January
2017,
https://www.wto.org/english/news_e/news17_e/trip_23jan17_e.htm.
16. World Trade Organization–Council for Trade-Related Aspects of Intellectual
Property Rights, Extension of the Transition Period under Article 66(1) of the TRIPS
Agreement for Least Developed Country Members, DECISION OF THE COUNCIL FOR TRIPS
IP/C/64 (June 11, 2013), https://www.wto.org/english/tratop_e/trips_e/ldc_e.htm.
17. World Trade Organization–Council for Trade-Related Aspects of Intellectual
Property Rights, Extension of the Transition Period under Article 66(1) of the TRIPS
Agreement for Least Developed Country Members for Certain Obligations with Respect to
Pharmaceutical Products, Decision of the Council of TRIPS IP/C/73 (November 6, 2016),
https://www.wto.org/english/news_e/news15_e/trip_06nov15_e.htm.
18. Article 66 of the TRIPS Agreement provides as follows:
In view of the special needs and requirements of least-developed country
Members, their economic, financial and administrative constraints, and their
need for flexibility to create a viable technological base, such Members shall not
be required to apply the provisions of this Agreement, other than Articles 3, 4
and 5, for a period of 10 years from the date of application as defined under
paragraph 1 of Article 65. The Council for TRIPS shall, upon duly motivated
request by a least-developed country Member, accord extensions of this period.
19. Article 66 of the TRIPS Agreement.
20. Id.
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Commentators have noted that the above flexibilities, transition
periods, and waivers are “the most important policy options available
to LDCs to facilitate affordable access.”21 In particular, the transition
periods are a critical policy instrument for the promotion of local
production of pharmaceuticals. This is because the non-recognition
and non-enforcement of patents on foreign products potentially
ensures that locally produced pharmaceuticals are not excluded from
the market due to the existence of patents.22 Moreover, the existing
literature suggests that strong patent protection would stifle
technological development in LDCs, because it would pose a barrier
to learning and copying, which are pre-requisites for technological
development.23
It is against this background that Article 66 of the TRIPS
Agreement provides for exemptions that offer LDCs some policy
space to facilitate the development of local production capacity. It
gives LDCs an opportunity “to do what developed countries
themselves had done to build their technological base.”24 This is done
through the creation of legal environments that permit the copying and
imitation of technologies. The transition periods, as renowned
intellectual property researcher Nirmalya Syam notes, have been
granted to ensure that LDCs are not hampered by intellectual property
rights “from taking suitable measures to develop a sound and viable
technological base in different industrial sectors.”25 They are a vital
tool for the development of a viable technological base, including
pharmaceutical production capacity.26 As a result, LDCs in the SADC
region have been presented with an opportunity to take advantage of
the transition period and develop viable local production capacity for
pharmaceuticals, and do what India has been doing for some time.27
21. Prerna Mingma Bomzan, Sanya Reid, & Mirza Alas Protilo, Submission of the LDC
Watch to the United Nations High-Level Panel on Access to Medicines, LDC WATCH, 2
(2016), http://www.unsgaccessmeds.org/inbox/2016/2/28/prerna-mingma-bomzan.
22. Syam, supra note 2, at 2.
23. UNCTAD Secretariat Geneva, The Least Developed Countries Report 2007:
Knowledge, Technological Learning and Innovation for Development, 103 (2007),
http://unctad.org/en/Docs/ldc2007_en.pdf.
24. Syam, supra note 2.
25. Id.
26. Mingma Bomzan et al., supra note 21, at 2.
27. See, e.g., William J Bennett, India Pharmaceutical Patent Law and Its Effects on
Novartis AG v Union of India, 13 WASH. U. GLOBAL L. REV. 535, 535–57 (2014); Sidonie
Descheemeker, India, Pharmacy of the Developing World: IP, Trade and Access to Medicine,
3 JURA FALCONIS JG, (2013). Prior to 2005, India was able to supply medicines to other
developing countries, because it was not granting product patents for pharmaceuticals. This
position changed in 2005 when India became fully compliant with the TRIPS Agreement and
started granting protection to pharmaceuticals. This means that India will not be able to supply
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One would accordingly expect LDCs to take advantage of these
transition periods and reform their laws to exclude pharmaceuticals
from patent protection. Therefore, it is unsurprising that throughout the
past decade there have been intensive discussions regarding how
SADC Member States can reform their laws to incorporate
flexibilities.28 These discussions have triggered and continue to trigger
patent law reform initiatives in the SADC region.29
However, these reforms have predominantly focused on how to
take advantage of the flexibilities in order to facilitate the importation
of affordable essential medicines from outside the SADC region.30
Much emphasis has been placed on how states can ensure that their
legal frameworks facilitate the importation of medicines from
countries like India. Little discussion has centered on how to take
advantage of paragraph 6 of the 30 August WTO Decision or Article
31 bis (3) to facilitate local or regional production of pharmaceuticals.
Consequently, the transition periods do not appear to have triggered
much country-level reforms among the SADC LDCs.31
Renowned IP and access to medicines advocates K.M.
Gopakumar and Sangeeta Shashikant rightly observe that the “use of
flexibilities within and outside the TRIPS Agreement has become the
generic medicines that were patented in the post-2005 era, unless compulsory licenses for
export are granted.
28. Breaking IP Barriers: Creating Pathways to Medicine Access (October 12–13,
2015),
http://arasa.info/files/5914/5329/2920/Breaking_IP_Barriers_Meeting_Report.pdf
(describing how countries of the SADC can use the WTO and the European Community
flexibilities for better access to affordable HIV/AIDS medicines); see also Tenu Avafia,
Jonathan Berger, & Trudi Hartzenberg, Monitoring Regional Integration in Southern Africa
Yearbook,
TRADE
LAW
CENTRE
FOR
SOUTHERN
AFRICA,
270–302,
http://westminsterresearch.wmin.ac.uk/11915/; Tenu Avafia, Jonathan Berger, & Trudi
Hartzenberg, The Ability of Select Sub-Saharan African Countries to Utilise TRIPs
Flexibilities and Competition Law to Ensure a Sustainable Supply of Essential Medicines: A
Study of Producing and Importing Countries, TRALAC WORKING PAPER NO 12 (2006),
http://www.section27.org.za/wp-content/uploads/2010/10/Avafia-Berger-andHartzenberg.pdf; SADC Pooled Procurement of Essential Medicines and Medical Supplies
Situational
Analysis
and
Feasibility
Study,
https://www.sadc.int/files/6614/1890/8516/SADC___SADC_POOLED_PROCUREMENT_
OF_ESSENTIAL_MEDICINES_AND_MEDICAL_SUPPLI. . ..pdf.
29. Lonias Ndhlovu, Access to Medicines under the WTO TRIPS Agreement: A
Comparative Study of Select SADC Countries (unpublished LLD Thesis), UNIVERSITY OF
SOUTH
AFRICA
(2014),
http://uir.unisa.ac.za/bitstream/handle/10500/14185/thesis_ndlovu_l.pdf?sequence=1.
30. Amal Nagah Elbeshbishi, TRIPS and Public Health: What Should African Countries
TRADE
POLICY
CENTRE
(2007),
Do?,
AFRICAN
http://repository.uneca.org/bitstream/handle/10855/13219/bib.%2054458.pdf?sequence=1
31. Mingma Bomzan et al., supra note 21, at 2, 13. The paragraph has been given formal
legal force by Article 31bis (3) of the TRIPS Agreement.
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dominant approach to addressing concerns over access to patented
medical products following the TRIPS patent regime.”32 They note,
however, that the strategy of using TRIPS flexibilities to facilitate
access to medicines is problematic, because it is based on a number of
“unrealistic and flawed assumptions.”33 One assumption is that all
countries have pharmaceutical manufacturing capabilities.34 This
assumption is not valid considering that most developing countries are
net importers of pharmaceuticals and are unable to use compulsory
licensing without relying on other countries.35 While the 30 August
WTO Decision allows for compulsory licensing for exportation and
importation of pharmaceuticals from producing countries, it has
largely been unused, because it is characterized by complex,
cumbersome, and tedious procedures and obligations.36

32. K.M. Gopakumar & Sangeeta Shashikant, Intellectual Property (IP) and Access to
Medical Products: A New Paradigm, (Submission to the United Nations Secretary-General’s
High
Level
Panel
on
Access
to
Medicines)
(2016),
http://www.unsgaccessmeds.org/inbox/2016/2/28/third-world-networkb.
33. Id. at 1.
34. Id.
35. Id.
36. Paragraph 2 of the Decision imposes the following obligations on the importing
Member:
(a) to notify the TRIPS Council about its intention to import a needed product or
needed products. The notification should specify “the name(s) and expected
quantities of the product(s) needed;” (b) where a product is protected in its
territory, to confirm that “it has granted or it intends to grant a Compulsory
License in accordance with Article 31of the TRIPS and the provisions of this
Decision;” (c) to take measures to ensure that the imported product(s) are utilized
in line with public health objectives. Accordingly, it is supposed “to take
reasonable measures within [its] means, proportionate to its administrative
[capacity] and to the risk of trade diversion to prevent re-exportation of the
products that have actually been imported into [its territory] under the system.”
The exporting Member on the other hand is obliged to issue a compulsory license
for the export of the needed product. The license should contain a number of the
following conditions: (a) the quantities to be manufactured and exported should
be restricted to those “necessary to meet the needs of the eligible importing
Member;” (b) the licensee must export “the entirety” of what it produces under
the license to the Member state that has notified the TRIPS Council of its need;
(c) the products must be “clearly identified as being produced under the system.”
Identification may take the form of specific marking, special packaging, special
coloring, shaping, and labeling (paragraph 2). The Decision acknowledges that
the distinct conditions may have an impact on pricing and only requires licensees
to distinguish their products to the extent that it is “feasible and does not have a
significant impact on price” (Paragraph 2(b) (ii)). The licensee is also obliged to
post some information on a website prior to shipment. The post should include
the following information (a) the amounts to be shipped to specific destinations
and (b) the features that distinguish the licensed products from the originators’
products. The provisions of paragraph 2 have since January 23, 2017, become
permanently incorporated into the TRIPS Agreement as paragraph 2 of the
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The need to stimulate local production of pharmaceuticals cannot
be over-emphasized. This is especially so, given that the patent
landscape in India is changing, and India is under increasing pressure
to stop making copies of newer medicines.
Another assumption is that there is global support for the use of
flexibilities.37 This assumption has limited validity. Currently,
developing countries, like India, are under a great deal of domestic and
external pressure to avoid utilizing flexibilities and to adopt TRIPSplus standards, which undermine TRIPS flexibilities.38 As a Joint
Agency Briefing Paper by HAI-Europe OXFAM observes, a variety of
strategies have been used to apply pressure on LMICs to not use TRIPS
flexibilities, and/or to introduce additional IP protections, called
“TRIPS-plus” provisions. In particular, EU-US trade policy has been
used to keep pushing a range of TRIPS-plus IP measures that support
the commercial interests of the pharmaceutical industry, while
damaging opportunities for innovation and access to medicines in
LMIC.39
Obviously, there is less pressure on LDCs, because they are
entitled to take advantage of transition periods, and their
pharmaceutical industry does not pose a major threat to developed
countries. Building up local production capacity within LDCs, by
taking advantage of the transition periods, offers a more viable and
sustainable solution to the problem of access to medicine that LDC
residents currently face.

Annex, to the TRIPS Agreement.
https://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm
37. Gopakumar & Shashikant, supra note 32.
38. Medecins Sans Frontieres (MSF), Untangling the Web of Antiretroviral Price
Reductions, 18th ed. (2016), http://www.msf.org/sites/msf.org/files/msf_access_utw.pdf.
According to the MSF report, India is under intense pressure, driven by multi-national
pharmaceutical companies, to reform its IP policies and laws. It is also under intense pressure
to sign Free Trade Agreements (FTAs) that will compel it to adopt TRIPS-plus standards and
effectively undermine its ability to utilize TRIPS flexibilities. One such agreement is the EU–
India draft FTA. Article 2(1) of the EU–India draft FTA provides that “this chapter shall
complement and further specify the rights and obligations between the Parties beyond those
under the TRIPS Agreement and other international treaties in the field of intellectual property
to which they are parties.” See generally Carlos M Correa, Negotiation of a Free Trade
Agreement European Union–India: Will India Accept TRIPS-Plus Protection?, OXFAM
GERMANY
AND
THE
CHURCH
DEVELOPMENT
SERVICE
(2009),
http://www.redge.org.pe/sites/default/files/correa_eu_india_fta.pdf.
39. Trading Away Access to Medicines—Revisited: How the European Trade Agenda
Continues to Undermine Access to Medicines, HAI-EUROPE AND OXFAM, 7 (2016),
https://www.oxfam.org/sites/www.oxfam.org/files/file_attachments/bp-trading-away-accessmedicines-290914-en.pdf.
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The critical point is that the overarching assumption behind the
dominant approaches to solving access to medicines problems is that
addressing patent-related barriers to access using flexibilities to
support importation of pharmaceuticals will be a panacea to all
problems of access and affordability.40 This is problematic considering
that obstacles to access to medicines are multiple and multifaceted.
Inadequate access to medicine in developing countries cannot just be
reduced to patents. It is attributable to many other factors, which have
largely been underemphasized in the dominant discourse. These
include limited local production capacity, high retail prices, duties,
taxes, markups, and other supply chain costs and limited lucrative
markets.41 Limited availability and poor affordability of some
medicines has also been attributed to market dominance by a limited
number of pharmaceutical companies. For instance, Beran et al.
contend, that the limited availability and poor affordability of insulin
is attributable to the domination of the market by three companies
which account for “90% of the global insulin market in terms of value
and volume.”42 Apart from stifling competition, the domination of
these three companies has also adversely impacted on availability of
insulin in many countries.43
Article 31bis of the TRIPS, which has supercededthe 30 August
Decision, deserves the attention of SADC policy makers, because it
has the potential to address both the problems of limited local
production and limited lucrative markets.
B. The Shrinking Role of India as the Pharmacy of the
Developing World
Patent law reform initiatives in the SADC region have reflected
the current overdependence on India as a source of affordable essential
generic medicines. This is unsurprising given the importance of India
as “the pharmacy of the developing world.”44 It is critical to ensure,
40. See, e.g., Amir Attaran , How Do Patents Affect Access to Essential Medicines in
Developing Countries, 23 HEALTH AFF. 155–66 (2004).
41. Margaret Ewen & David Beran, Access to Insulin: Current Status and Global Policy
Implications, Contribution for the United Nations Secretary-General’s High Level Panel on
Access to Medicines (2016); David Beran, Margaret Ewen, & Richard Laing, Constraints and
Challenges in Access to Insulin: A Global Perspective, 4 LANCENT DIABETES ENDOCRINAL
275–85 (2016), http://www.unsgaccessmeds.org/inbox/2016/2/25/margaret-ewen-and-davidberan.
42. Margaret Ewen & Richard Laing, Constraints and Challenges in Access to Insulin:
DIABETES
ENDOCRINAL
(2016),
A
Global
Perspective,
LANCENT
http://www.unsgaccessmeds.org/inbox/2016/2/25/margaret-ewen-and-david-beran.
43. Id.
44. Existing literature reveals that 76 percent of the generic ARVs used in low and
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however, that other regions of the world, including the SADC
countries, establish their own manufacturing bases. This is for a
number of reasons.
First, the policy space available to India to produce and export
generic medicines has been largely undermined. Prior to 2005, India
was not obliged to provide product patent protection for
pharmaceuticals.45 However, it is now obliged to comply fully with the
TRIPS Agreement.46 This makes it difficult for Indian companies to
make and export generic versions of post-2005 patented
pharmaceuticals to developing countries and LDCs.47 Thus, the future
access scenario for newer pharmaceuticals looks bleak. Emerging
evidence suggests that the cost of treatment is on the increase, because
new pharmaceuticals are widely patented in developing countries,
including India.48 The future looks even more problematic for the
SADC region, because most SADC Member States routinely provide
patent protection for pharmaceuticals through the African Regional
Intellectual Property Organization (ARIPO) system.49 This has the
potential to inhibit access to new generations of pharmaceuticals,
including antiretroviral (ARVs) drugs. The above trend is worrisome
given that the number of patients who are resistant to older generations
of ARVs and need newer ARVs is on the increase.
Second, India is increasingly being pressured by pharmaceutical
corporations and developed countries to reform its laws to provide
middle-income countries originate from India. SeeMSF, supra note 37. Ninety-six percent of
the HIV medicines donor-funded programs rely on are generics, mostly from India. See HIV
Medicines-Technology and Market Landscape, UNITAID (March 2014), http: //www.
unitaId.eu/images/marketdynamics/publications/HIV-Meds-Landscape-March.pdf.
45. William Greene, The Emergence of India’s Pharmaceutical Industry and
Implications for the U.S. Generic Drug Market, OFFICE OF ECON. WORKING PAPER, U.S.
INTERNATIONAL TRADE COMMISSION NO. 2007-05-A, 1 (2007).
46. Id.
47. Wilbert Bannenberg, Trade, TRIPS and Access to Medicines: Challenges and
Opportunities for the SADC Region, BRIEFING PAPER FOR SADC MEMBER STATES
CONSULTATION, BIRCHWOOD , JOHANNESBURG, SOUTH AFRICA, (September 18, 2012),
http://www.sarpam.net/wp-content/uploads//images+docs/3-the-programme/d-trips-tradeaccess-to-medicines/supporting-documents/Briefing-paper-ENGLISH.pdf;
NEPAD,
Strengthening Pharmaceutical Innovation in Africa Designing Strategies for National
Pharmaceutical Innovation: Choices for Decision Makers and Countries (Final Study Report)
29 (2010).
48. Ellen ‘t Hoen et al, Driving a Decade of Change: HIV/AIDS, Patients and Access to
Medicines
for
All,
14
J.
INT’L
AIDS
SOC.
1-12
(2011),
http:
//www.jiasociety.org/content/14/1/15.
49. Sangeeta Shashikant, The African Regional Intellectual Property Organization
(ARIPO) Protocol on Patents: Implications for Access to Medicines, 56 SOUTH CENTRE–
PAPERS,
19
(2014),
https://www.southcentre.int/wpRESEARCH
content/uploads/2014/11/RP56_The-ARIPO-Protocol-on-Patents_ENl.pdf.
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more protection to patent holders than it is required to do under the
TRIPS Agreement.50 India is also being pressured to relax its standards
in order to extend patent protection to pharmaceutical products that
would otherwise not pass the existing criteria for patentability.51 This
effectively constrains its available policy space to use flexibilities in
favor of the developing world thus undermining India’s role as a
supplier of generic pharmaceuticals.52
Third, as a sovereign state, India has its own pharmaceutical R&D
priorities, which might not necessarily coincide with the pressing
public health needs of the SADC region. Therefore, it would be myopic
to place too much reliance on it. As Ellen ‘t Hoen et al. observe:
“Without production sources, the countries that rely on importation
will find it hard to source low-cost medicines.”53
The importance of developing a regional strategy for addressing
the gap that the ongoing Indian law and policy reforms might create
for SADC countries cannot be over-emphasized. Such a strategy needs
to put strong emphasis on local or regional production of
pharmaceuticals. The development of local and regional production
capabilities for SADC countries would ultimately help in the
development of regional pharmaceutical R&D capabilities for the
SADC.
Ironically, most pro-access advocates and SADC policy makers
tend to define the problem of access too narrowly by concentrating on
the question of affordability and how to facilitate importation of
pharmaceuticals from countries like India. This is overly reductive and
ultimately unhelpful as a way of finding sustainable solutions to the
problem of access. As Reid and Mirza observe:
Developing local or regional pharmaceutical
production capacity is a fundamental aspect of access
50. Brook Baker, Will the Modi Government Succumb to U.S. and Industry Pressure to
Modify its Pro-Access Pharmaceutical Patent Policy? 25 EXPERT OPINION ON THERAPEUTIC
PATENTS
J.
625–28
(2015),
http://www.tandfonline.com/doi/full/10.1517/13543776.2015.1018890.
51. Medecins Sans Frontieres (MSF), A Timeline of U.S. Attacks on India’s Patent Law
and
Generic
Competition,
MSF
ACCESS
CAMPAIGN
(2015),
https://www.msfaccess.org/sites/default/files/MSF_assets/IP/Docs/IP_factsheet_TimelineUS
PressureIndia_ENG_2014.pdf.
52. MSF, Decisions Around HIV Treatment in 2015: Seven Ways to Fail, Derail or
Prevail(2015),
https://www.msfaccess.org/sites/default/files/HIV_Brief_HIV_Fail_Derail_or_Prevail_ENG
_2015.pdf.
53. Ellen ‘t Hoen et al., supra note 48, at. 7
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to pharmaceutical products and thus imperative to the
fulfillment of the right to health. There is growing
concern of the impact of the overwhelming reliance on
pharmaceutical imports on affordability, availability
and long term sustainability.54
C. The Innovation–Access Balance
In order to provide sustainable access to medicine, two broad
challenges must be addressed. The first challenge is how to make
existing medicines affordable to the poor. The second and more
intractable challenge relates to how to devise new ways of stimulating
R&D and local production of new medicines for diseases endemic in
developing countries.
Access to medicines will only be achieved if medicines are
developed and manufactured in the first place, and development
requires the creation of a legal framework that is supportive of R&D
and local/regional production. Such a legal and policy framework must
address both the need to get currently available pharmaceuticals to the
developing world and the need to encourage research into future useful
products that benefit the poor (as well as local/regional production of
the same). This would be in line with the third goal of the UN Strategic
Development Goals (SDGs), which contain the following bold
commitment:
Support the research and development of vaccines and
medicines for the communicable and noncommunicable diseases that primarily affect
developing countries, and provide access to affordable
essential medicines and vaccines, in accordance with
the Doha Declaration on the TRIPS Agreement and
Public Health, which affirms the right of developing
countries to use to the full provisions in the Agreement
on Trade-Related Aspects of Intellectual Property
Rights regarding flexibilities to protect public health,
and, in particular, provide access to medicines for all.
These are the challenges that SADC Member States have recently
been attempting to surmount. Thus, the ensuing discussion focuses on
the legal and policy reforms that have recently been taking place in the
SADC region in order to stimulate local production of

54. Mingma Bomzan et al., supra note 21, at 6.
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pharmaceuticals.
II. THE SADC REGION AND ACCESS TO PHARMACEUTICAL
PRODUCTS: SADC AND ITS DISEASE BURDEN
The SADC was established in 1992 by the Treaty of the Southern
African Development Community.55 The objective of the treaty was
“to promote sustainable and equitable economic growth and socioeconomic development that will ensure poverty alleviation, with the
ultimate objective of its eradication, enhance the standard and quality
of life of the people of Southern Africa and support the socially
disadvantaged.”56 Regional integration is regarded as a tool for
achieving these objectives.
The SADC has fifteen Member States, namely: Angola,
Botswana, Democratic Republic of the Congo (DRC), Lesotho,
Madagascar, Malawi, Mauritius, Mozambique, Namibia, Seychelles,
South Africa, Swaziland, Tanzania, Zambia, and Zimbabwe.57 Eight of
these Members States are classified as LDCs. These are Angola,
Malawi, Mozambique, Zambia, DRC, Lesotho, Tanzania, and
Madagascar.58 The defining characteristics of LDCs include poverty,
socio-economic inequalities and injustices, low human development,
economic vulnerability, limited resilience to natural disasters and
limited technological development.59 The SADC has a population of
approximately 277 million people.60
The SADC region is one of the most heavily disease-burdened
regions of the world. Its Members continue to bear a disproportionate
burden of HIV/AIDS, tuberculosis (TB), and malaria.61 Noncommunicable diseases (NCDs) are also on the increase, especially in

55. The SADC was restructured in 2002 pursuant to major amendments to the 1992
Treaty. The amendments include, a number of provisions relevant to access to medicines.
These include Article5(a) cited in note 36 and Article 5(i) which provides that one of the
objectives of the SADC shall be to “combat HIV/AIDS and other deadly or communicable
diseases.”
56. Id.
57. See
Southern
African
Development
Community,
Member
States,
http://www.sadc.int/member-states/.
58. See United Nations Committee for Development Policy, List of Least Developed
Countries, http://www.un.org/en/development/desa/policy/cdp/ldc/ldc_list.pdf.
59. Mingma Bomzan et al., supra note 21, at 2.
60. SADC Pharmaceutical Programme, SADC Pharmaceutical Business Plan, 5 (2015–
2019) [hereinafter SADC PBP (2015–2019)].
61. See
SADC,
Communicable
Diseases,
http://www.sadc.int/themes/health/communicable-diseases/.
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the African middle class.62
The SADC’s integration agenda primarily focuses on trade,
economic growth, and development.63 However, the recognition that
Member States cannot address these challenges individually has
prompted SADC Members to include health on the SADC integration
agenda. Consequently, the integration agenda prioritizes the social and
human development aspects of integration. This includes “fostering
cooperation in addressing health challenges influenced by the high
burden of both communicable diseases, such as HIV/AIDS, TB, and
malaria, and NCDs, such as diabetes, hypertension, cancer, and heart
problems.”64 The integration agenda also recognizes the interface and
interaction among poverty alleviation, regional integration, economic
development, and human rights.65
Equitable access to medicines remains illusory for the majority of
SADC citizens.66 While some SADC Member States have relatively
good access to medicines, others do not.67 There are also wide
disparities in terms of access within specific countries.68 There are a
number of barriers to the availability of good quality and affordable
medicines in the SADC region. These barriers include inadequate
national medicine budgets; over-dependence on imported medicines;
inadequate R&D; inadequate local production; under-utilization of
installed production capacities; poor procurement and supply
62. WHO, Baseline Assessment of the Pharmaceutical Situation in Southern African
Development
Community
Countries:
Fact
Book
(2009),
http://www.who.int/medicines/areas/coordination/coordination_assessment/en/index3.html.
63. Article 5 of the SADC Treaty; Amos Saurombe, Regional Integration Agenda for
SADC “Caught in the Winds of Change” Problems and Prospects, 4 J. INT’L COMM. L. &
TECH. 100–06 (2009).
64. SADC Pharmaceutical Programme, SADC Pharmaceutical Business Plan, 3 (2007–
2013),
https://www.unido.org/fileadmin/user_media_upgrade/What_we_do/Topics/Business__inves
tment_and_technology_services/CUP/Pharma/Literature/SADC_PHARMACEUTICAL_BU
SINESS_PLAN_-APPROVED_PLAN.pdf [hereinafter SADC PBP (2007–2013)].
65. Article 5 of the SADC Treaty.
66. SADC, Strategy for Pooled Procurement of Essential Medicines and Health
Commodities,
1
(2013–2017),
https://www.sadc.int/files/7614/1898/8449/SADC___Strategy_for_Pooled_Procurement_of_
Essential_Medicines_and_Health_Commodities.pdf [hereinafter SADC PPEM (2013–2017)].
67. SADC, Pooled Procurement of Essential Medicines and Medical Supplies Situational
Analysis
and
Feasibility
Study,10
(2012),
https://www.sadc.int/files/6614/1890/8516/SADC___SADC_POOLED_PROCUREMENT_
OF_ESSENTIAL_MEDICINES_AND_MEDICAL_SUPPLI. . ..pdf[hereinafter
SADC
Feasibility Study]; WHO, Baseline Assessment of the Pharmaceutical Situation in Southern
African Development Community Countries: Fact B 2009ook,
1 (2009),
http://www.who.int/medicines/areas/coordination/sadc_final.pdf?ua=1
68. Id.
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management systems; limited supplier base and small quantity
requirements69; human resource constraints; taxes and tariffs on raw
materials and finished products; poor health care infrastructure and
systems; small markets; and unaffordable prices.70 Outdated IP laws
are also implicated, especially in developing member states.71 All
SADC states are Members of the WTO and are obliged to comply with
minimum standards of IP protection, including patents.72 They are also
entitled to take advantage of various flexibilities and waivers available
to them under the TRIPS legal framework.
The problem of inadequate access to medicines is also aggravated
by the fact that the majority of SADC citizens have no medical
insurance. This means that they procure medicines out of pocket.73
Given low earning capacities, medicine is generally out of reach for
them.74 Therefore, they rely on under-resourced public-sector health
service providers for their needs.75 Thus, the individual markets of
Member States are not attractive to pharmaceutical manufacturers.
This has implications for affordability and sustained access.
A. The SADC Pharmaceutical Market
The estimated SADC pharmaceutical market is U.S. $4.1 billion,
largely dominated by generic and patented pharmaceuticals from
outside Africa.76 In terms of HIV/AIDS specific pharmaceuticals,
patented pharmaceuticals account for thirty-seven percent while
generic pharmaceuticals account for sixty-three percent.77
Local manufacturers account for twenty-four percent of the
SADC pharmaceutical market.78 The SADC pharmaceutical market is
largely dominated by South Africa, which has some limited capacity
to produce active pharmaceutical ingredients (APIs).79 The
69. According to the SADC-PBP (2015-2019), supra note 59, these factors effectively
undermine the procurement-bargaining power of Member States.
70. SADC PBP (2015–2019), supra note 60, at 18.
71. SADC PBP (2007-2013), supra note 64, at 9.
72. TRIPS Agreement, supra note 1.
73. Insight Actuaries and Consultants Effective Health Financing Models in SADC:
Three Case Studies, FINMARK TRUST, 4 (2016), http://www.finmark.org.za/wpcontent/uploads/2016/06/regional-sadc-case-studies.pdf
74. Id.
75. Id.
76. SADC SPPEM (2013-2017), supra note 66, at 11.
77. SADC Feasibility Study, supra note 67, at 30.
78. SADC, Feasibility Study on Regional Manufacturing of Medicines and Health
Commodities, Volume 1, (Final Report) SADC-SHD&SP/CD/C39/2014, 30 (January 2016).
79. International Finance Corporation (IFC), The Business of Health in Africa:
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pharmaceutical industry outside South Africa primarily focuses on
producing “non-complex, high volume, essential products, such as
basic analgesics, simple antibiotics, anti-malarial drugs, and
vitamins.”80
There are a number of factors that undermine local production of
pharmaceuticals in the SADC region. These factors include strong
competition from Indian manufacturers; lack of local supply of raw
materials and overdependence on imported raw materials (from India
and China); inadequate incentives (low taxes, preferential treatment,
and loans); and lack of policy coherence on tariffs.81 Additional factors
include inadequate usage of existing pharmaceutical production
facilities, due to lack of enabling policy environments; inadequate
human resource capacity; high operating costs, rendering it more cost
effective to import; financial resource constraints; obsolete equipment;
inadequate pharmaceutical manufacturing policies/strategies; and
absence of and inadequate procurement policies in favor of local
manufacturers.82 Another factor that undermines local production is
limited effective demand for local products in individual SADC
LDCs.83 SADC LDCs generally depend on development partners for
their pharmaceutical supplies. These development partners either
require World Health Organization (WHO) prequalification as
condition for procurement or source their products from elsewhere.84
This disadvantages some SADC manufacturers who have challenges
meeting international quality and other WHO prequalification
standards.85 As a result, Asian countries have a comparative advantage
Partnering the Private Sector to Improve People’s Lives, International Finance Corporation,
World
Bank
Group,
76
(2007),
https://www.unido.org/fileadmin/user_media/Services/PSD/BEP/IFC_HealthinAfrica_Final.
pdf
80. Id.; see also SADC PBP (2007–2013), supra note 64, at 9-10.
81. SADC PBP (2007–2013), supra note 63, at 17; EQUINET, Enhancing Local
Medicine Production in East and Southern Africa, POLICY SERIES NO.39, 2 (2014),
http://www.equinetafrica.org/sites/default/files/uploads/documents/EQ_GHD_Meds_polbrie
f39_2014.pdf; Southern and Eastern African Trade, Information and Negotiations Institute
(SEATINI) and Centre for Human Rights and Development (CEHURD)Literature review on
bottlenecks to essential medicines production and procurement in East and Southern Africa,
(2013),
http://www.equinetafrica.org/sites/default/files/uploads/documents/Diss_96_GHD_Litreview
_meds_May2013.pdf.
82. SADC Feasibility Study, supra note 67, at 16.
83. EQUINET
supra
note
81,
at
2,
http://www.equinetafrica.org/sites/default/files/uploads/documents/EQ_GHD_Meds_polbrie
f39_2014.pdf.
84. Todd Dickens, The World Medicines Situation in 2011: Procurement of Medicines,
(WHO-Geneva), http://apps.who.int/medicinedocs/documents/s18769en/s18769en.pdf.
85. Id. at 23.
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over SADC producers due to a number of factors, in particular, human
resources, basic costs of production, and experience and economies of
scale.86 Consequently, it is considered cheaper to source medical
products from India than to procure within the region. Therefore, a
need exists to create an enabling legal and policy environment for local
or regional production of pharmaceuticals products within the region.
Given the limited manufacturing base in the region, SADC LDCs
have relied on imports, especially from India, as a source of affordable
generic pharmaceuticals for their populations. Eighty-five percent of
these HIV/AIDS generics are produced outside the region and fifteen
percent are produced in the region.87
The burden of procuring and providing medicines has essentially
been borne by development partners.88 As observed above, the future
access scenario looks bleak, given that India can no longer easily make
newer versions of generic drugs for export. Therefore, the challenge
for SADC countries has been to find a more reliable source of secondline and third-line (or salvage) ARVs.89 This concern has resulted in
the countries’ increasingly inward search on this issue, and they are
now actively exploring options for producing generic essential
medicines within the SADC region itself.90
Given the magnitude of these problems and the recognition that
individual countries have serious capacity constraints, SADC Member
States have resolved to adopt collective approaches to addressing
access to medicine problems.91 Collective approaches are further seen
as a way of enhancing market efficiencies and harnessing economies
of scale.92

86. Fei-fei Yue & Ying-ming Yue, Study of Comparative Advantages of Chinese and
Indian Pharmaceutical Industries under Globalization, 4 MGNT SCI. 82 (2010).
87. Id.
88. SADC SPPEM (2013–2017), supra note 66, at 9.
89. Salvage treatment becomes essential when treatment options become limited due to
resistance. According to MSF, the current lowest price of the salvage drug Darunavir +
Raltegravir and Eltravirine (DRV+RAL+ETV) is US $1,859 per person/per year (Untangling
the Web, 10, 2016).
90. SADC PBP 2015–2019, supra note 60.
91. Id.
92. SADC, Feasibility Study, supra note 67.
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III. RECENT LAW AND POLICY REFORMS
A. Regional Level Reforms
The desire to find collective solutions to the common problem of
inadequate access to medicines has motivated SADC states to develop
laws, policies, and programs that seek to address this problem in a
collaborative manner. These include two major developments. First,
the adoption of the legally enforceable, SADC Protocol on Health in
1999.93 Article 29 of the Protocol obliges state parties to “cooperate
and assist one another in the harmonization of procedures of
pharmaceuticals, quality assurance and registration, production,
procurement, and distribution of affordable essential drugs.”94 And
second, the adoption of the SADC Pharmaceutical Business Plan
(PBP) by SADC Health Ministers in 2006. The PBP was valid from
2007 to2013.95 A new plan has since replaced it and covers the period
from 2014 to 2019.96 The PBP is designed to operationalize the SADC
pharmaceutical program.97 Its stated overall objective is to ensure “the
availability of essential medicines including African Traditional
Medicines to reduce the disease burden in the region.”98 At a more
specific level, the SADC PBP seeks to “improve sustainable
availability and access to affordable, quality, safe, efficacious essential
medicines including African Traditional Medicines.”99
B. SADC PBP (2015-2019): Strategic Priority 2
The SADC has recognized promoting local and regional
production capacity of the pharmaceutical industry as one of the key
strategic priorities of the PBP. Strategic Priority 2 of the plan focuses
on “creating an enabling environment that will maximize the research
and production capacity of local and regional pharmaceutical
industries in terms of generic essential medicines.”100 The strategies
adopted to achieve this end include promotion of joint ventures and
public-private partnerships, and removal of tariff and policy barriers
on raw materials.101 The envisaged output of the plan is “50% increase
93.
94.
95.
96.
97.
98.
99.
100.
101.
SADC

Protocol on Health in the Southern African Development Community (1999).
Article 29(a)(b).
SADC PBP (2000–2013), supra note 66.
SADC PBP (2015–2019), supra note 60.
Id. at 9.
Id.at 4.
Id.
SADC PBP (2015-2019), supra note 60, at 19.
The rationale behind these initiatives is that they would enhance the viability of the
pharmaceutical sector by reducing production costs, harnessing private and public
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in local production and availability of essential medicines.”102
C. Opportunities to Build a Pharmaceutical Industry in the
Region
Prior to 2005, the prospects of building a viable generics industry
in SADC were slim because of fierce competition from India and
China. These countries have a comparative advantage over SADC
countries when it comes to the production of raw materials and finished
products. However, as the SADC Feasibility Study observes, the full
implementation of the TRIPS Agreement by India presents an
opportunity for the SADC pharmaceutical sector.103 This is because
India cannot easily make generic versions of pharmaceuticals that were
patented post-2005.104 Manufacturers in SADC LDC Members would
be entitled to make generics until 2033.105
The PBP 2015-2019 implicitly recognizes the fact that individual
Member States do not have large enough markets to support a viable
pharmaceutical industry.106 It therefore sets out strategies that seek to
take advantage of TRIPS flexibilities to improve pharmaceutical
manufacturing and distribution capabilities at the regional level.
Specifically, the PBP recognizes that the TRIPS Agreement does not
oblige LDCs to implement patent and data protection provisions until
2033 or even beyond.107 According to the PBP, this presents an
opportunity for SADC Member States, including LDCs, to take
advantage of the transition period and develop their local production
capacity.108 This opportunity was initially recognized in the SADC
PBP 2007-2013, which provided as follows: “A second window of
opportunity which could be exploited is contained in paragraph 6 of
the WTO decision of August 30, 2003, which allows regional blocs
with at least half of its membership being LDCs to trade in
pharmaceuticals within the bloc without restrictions.”109

resources, and increasing productivity.
102. Id. at 26.
103. SADC, Pooled Procurement of Essential Medicines and Medical Supplies
Situational
Analysis
and
Feasibility
Study,
(2012),
https://www.sadc.int/files/6614/1890/8516/SADC___SADC_POOLED_PROCUREMENT_
OF_ESSENTIAL_MEDICINES_AND_MEDICAL_SUPPLI. . ..pdf
104. SADC Feasibility Study, supra note 67, at 30.
105. Decision of the Council for TRIPS of 6 November 2015.
106. SADC PBP (2015–2019) supra note 60, at 17.
107. Id. at 17, 20.
108. Id. at 20.
109. SADC PBP (2007–2013), supra note 64, at 12.
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Paragraph 6 of the 30 August WTO Decision endeavors to solve
the problems of insufficient manufacturing capacity and the absence
of lucrative domestic markets by attempting to harness economies of
scale using regional trade groupings.110 The paragraph exempts
developing countries or LDCs that are members of certain regional
trade agreements from some TRIPS obligations.111 These include the
requirement under Article 31(f) of the TRIPS Agreement that
compulsory licensing should be, predominantly, for domestic use.112
The only countries that can take advantage of this exemption or
waiver, however, are those that are members of regional trade
agreements, whose membership comprises at least fifty percent
LDCs.113 The scope of the waiver is to enable members to produce or
import pharmaceutical products under a compulsory license so those
members can export to the markets of other developing or LDC
members within the trade block that share the health problem in
110. The paragraph reads as follows:
With a view to harnessing economies of scale for the purposes of enhancing
purchasing power for, and facilitating the local production of, pharmaceutical
products: “where a developing or least-developed country WTO Member is a
party to a regional trade agreement within the meaning of Article XXIV of the
GATT 1994 and the Decision of 28 November 1979 on Differential and More
Favourable Treatment Reciprocity and Fuller Participation of Developing
Countries (L/4903), at least half of the current membership of which is made up
of countries presently on the United Nations list of least developed countries, the
obligation of that Member under Article 31(f) of the TRIPS Agreement shall be
waived to the extent necessary to enable a pharmaceutical product produced or
imported under a compulsory license in that Member to be exported to the
markets of those other developing or least developed country parties to the
regional trade agreement that share the health problem in question. It is
understood that this will not prejudice the territorial nature of the patent rights in
question”; (SADC is a regional body notified Article XXIV of the GATT).
111. Paragraph 6 (i) of the 30 August Decision. The Paragraph has now become
permanently incorporated into the TRIPS by Article 31bis (3) which provided as follows:
With a view to harnessing economies of scale for the purposes of enhancing
purchasing power for, and facilitating the local production of, pharmaceutical
products: where a developing or least developed country WTO Member is a party
to a regional trade agreement within the meaning of Article XXIV of the GATT
1994 and the Decision of 28 November 1979 on Differential and More
Favourable Treatment Reciprocity and Fuller Participation of Developing
Countries (L/4903), at least half of the current membership of which is made up
of countries presently on the United Nations list of least developed countries, the
obligation of that Member under Article 31(f) shall not apply to the extent
necessary to enable a pharmaceutical product produced or imported under a
compulsory licence in that Member to be exported to the markets of those other
developing or least developed country parties to the regional trade agreement
that share the health problem in question. It is understood that this will not
prejudice the territorial nature of the patent rights in question.”
112. Id.
113. Id.
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question.114
The waiver attempts to harness the economies of scale to enhance
the existing purchasing power through use of regional trade blocs, and
promote and facilitate local production of pharmaceutical products.115
The PBP 2015-2019 recognizes the potential utility of the 30
August WTO Decision as a tool for promoting local/regional
production of pharmaceuticals in key Strategic Area 7.116 Paragraph
7(v) of the PBP stipulates that, in order to facilitate trade in
pharmaceuticals within the region, SADC members will “utilize the
paragraph 6 system or article 31bis of the TRIPS Agreement to
facilitate local production for export; or importation for re-exportation
within SADC as a regional bloc.”117 The difficulty is that SADC LDCs
may not have the capacity to reap the full benefits of this waiver
because of the absence of lucrative domestic markets, human resource
constraints, inadequate technological capacity, poor infrastructure, and
inadequate public funding of R&D.118 Some country studies have
revealed, however, that various individual SADC countries have some
production capacity and could benefit from the economies of scale that
Article 31bis attempt to harness.119 Article 31 bis is flexible enough to
allow for the possibility of the manufacture of pharmaceuticals to take
place in developing country member states. Therefore, SADC
countries can explore the possibilities of harnessing the R&D, as well
as production and procurement capabilities of some of its developing
member states, including South Africa, to achieve this objective.
Moreover, while individual SADC countries and the region at
large may not represent lucrative markets for big pharmaceutical
companies, the SADC region may be a large enough market for
114. Id.
115. Id.
116. SADC PBP (2015–2019), supra note 60, at 20.
117. Id.
118. LDC Watch, supra note 21, at 4.
119. John H Amuasi, Technology Transfer and Local Manufacturing of Pharmaceuticals:
The South African Case, African Dialogue on Technology Transfer for Local Manufacturing
Capacity on Drugs and Vaccines Cape Town, South Africa, ICTSD AND UNCTAD, WITH THE
SUPPORT OF THE WHO AND THE EU COMMISSION, 10–11 (December 2009), ,
http://www.ictsd.org/downloads/2009/12/amuasi-paper-edited.pdf; United Nations Industrial
Development Organization Pharmaceutical Sector Profile Zimbabwe: Global UNIDO
Project: Strengthening the local production of essential generic drugs in least developed and
developing
countries,
(2011),
http://apps.who.int/medicinedocs/documents/s18701en/s18701en.pdf; German Technical
Cooperation Agency (GTZ),The Viability of Local Pharmaceutical Production in Tanzania, ,
4, 43 (2007), https://www.unido.org/fileadmin/user_media/Services/PSD/BEP/Tanzania.pdf.
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regional manufacturers. Hence, the Article 31 bis attempts to create
viable markets by allowing companies in individual countries to
produce for export within the region.
Some LDCs in the region already have some pharmaceutical
manufacturing capacity, albeit limited. As a result they may be
potential leaders in manufacturing pharmaceuticals for the SADC
region. A recent study on Tanzania, for instance, concluded that there
is a case for promoting local production in Tanzania.120 This is
especially because the public sector, which is mostly supported by
donors, represents a relatively significant market and “offers realistic
options for a viable business.”121 The same can be said of other SADC
countries.122 The study also concludes that a regional approach to
pharmaceutical production would make more business sense.123 The
only drawback is that most domestic companies do not meet WHO
prequalification standards to be eligible for international donor
financing.124
LDCs within the region could also explore the possibility of
collaborating with Indian, Chinese, Brazilian, U.S., and EU
manufacturers to open generic plants within their territories, which
would service the whole SADC region. Such collaborations are already
emerging within the region and in the Common Market for Eastern and
Southern Africa (COMESA) area. Mozambique, for instance, has
recently started producing generic and older versions of ARVs with
assistance from Brazil.125
Moreover, utilization of this system would facilitate “the
development of a viable technological base, including pharmaceutical
production capacity.”126 This is because the system endeavors to solve
the problem of limited markets for pharmaceuticals within individual
countries and attempts to harness economies of scale within regional
blocs. The flexibility to produce for export would render the SADC
region attractive to generic pharmaceuticals investors and would hence
help in the development of a technological base for the region.
Therefore, the system provides a window of opportunity for countries

120. Id.
121. GTZ, The Viability of Local Pharmaceutical Production in Tanzania, 4, 43 (2007),
https://www.unido.org/fileadmin/user_media/Services/PSD/BEP/Tanzania.pdf.
122. South Africa, Zimbabwe, Zambia and Mozambique.
123. Id. at 44.
124. SADC Feasibility Study, supra note 67.
125. Bannenberg, supra note 47, at 3.
126. Mingma Bomzan et al., supra note 21.
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within the SADC region to do what India has been doing for some
time.
Developed countries also have an obligation to perform in the
development of a viable pharmaceutical base for the SADC region.
Article 66 of the TRIPS Agreement obliges them to “provide
incentives to enterprises and institutions in their territories for the
purpose of promoting and encouraging technology transfer to leastdeveloped country Members in order to enable them to create a sound
and viable technological base.”127 However, there is evidence
suggesting that developed countries have not honored their
commitment to transfer technology to LDCs.128 Nevertheless, this
should not be a reason to rule out local production. Rather, it should be
a reason to advocate for developed countries to honor their
commitments. Given that SADC LDCs have no capacity to make
newer pharmaceuticals, including ARVs, they would require a lot of
technical and financial support from development partners to develop
production capabilities.
Moreover, there is emerging evidence that developing countries
have started transferring essential technologies to developing countries
and LDCs. Thailand, for example, transferred technology for the
formulation of a fixed-dose combination of stavudine, lamivudine, and
nevirapine to two companies based in Tanzania and the DRC.129 Action
Medeor, a German non-governmental organization (NGO), has been
involved in an initiative to develop a fixed dose combination
formulation of tenofovir, lamivudine, and efavirenz in collaboration
with Muhimbili University in Tanzania. The expectation is that the
technology would be transferred to local manufacturers at no cost.130
Similarly, the Brazilian government was recently involved in a transfer
of technology initiative through the Oswaldo Cruz Foundation
(FIOCRUZ) to the government of Mozambique, which constructed a
new ARV manufacturing plant.131
Technology transfer by itself, however, would not facilitate
technological development in LDCs. Effective use of such technology
127. Doha Declaration, supra note 3, para. 7. The Doha Declaration also reaffirms “the
commitment of developed-country Members to provide incentives to their enterprises and
institutions to promote and encourage technology transfer to least-developed country
Members pursuant to Article 66.2.”
128. WHO Pharmaceutical Production and Related Technology Transfer (2011),
http://www.who.int/phi/publications/Local_production_and_access_to_medicines.pdf.
129. Id. at 29
130. Id.
131. Id.
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in an LDC context would require building the capacity of
pharmaceutical companies in LDCs to assimilate such knowledge and
“adopt technical know-how.”132 Domestic patent legislation can also
facilitate this process by ensuring that patents are not granted unless
the inventor describes the invention in such a way that it can be worked
by locals. SADC countries may wish to adopt a provision similar to
Section 21(10) of the Ugandan Industrial Property Act, 2014, which
provides that the registrar may, before granting the patent, require the
description in a foreign patent application to be adapted to the ordinary
skill in the art of the citizens of Uganda so as to ensure technology
dissemination.133
SADC countries would also need to adopt a regional strategy to
create a viable market. The recently adopted SADC Strategy for
Pooled Procurement of Essential Medicines and Health Commodities
is, thus, a step in the right direction.134 This is because it endeavors to
eliminate duplication of efforts and to harness economies of scale.135
To conclude, the system represents a significant policy option
available to SADC member states to stimulate access to affordable
medicine at the regional level. Given that some SADC members are
also members of COMESA136, Article 31 bis presents an amazing
potential for smaller SADC states to harness economies of scale.
Uganda, a COMESA member, has already amended its law to support
the manufacture and export to other countries that share similar health
problems.137 These would include SADC members who double as
COMESA members.138 Section 44(e) of the Ugandan Act provides that
unauthorized use of a patented invention does not amount to an
infringement where the manufacture and export of a patented
healthcare invention to another country

132. Syam, supra note 2, at 4.
133. Section 21(10).
134. The SADC Strategy for Pooled Procurement of Essential Medicines and Health
Commodities was adopted in 2013 and will expire in 2017. The stated aim of the strategy is
to “facilitate regional cooperation in the procurement of essential medicines and health
commodities thus ensuring access to affordable, safe, effective and quality–assured products.”
The idea behind the strategy is to promote market efficiencies and bargaining power through
regional approaches to procurement. It is hoped that pooled procurement would increase
access to essential medicines and the availability of orphan drugs that are characterized by
procurement challenges owing to the limited amounts required by individual states.
135. Paragraph 6(i) of the 30 August Decision.
136. These include Malawi, Mauritius, Zambia, Seychelles, Mauritius, Zimbabwe, and
Tanzania.
137. Section 44(e) of the Uganda Industrial Property Act.
138. See supra note 139.
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addresses a health need identified by the other country,
where(i) the product is either not patented in the third
country; or
(ii) the government of another country has authorized
use of the patent without the consent of the patent
owner and the production for export of the invention is
intended only for the market of the third country.139
These provisions position Uganda perfectly to take
advantage of the 30 August waiver to export
pharmaceuticals to COMESA and some SADC nations.
IV. DOMESTIC LEVEL REFORMS
All SADC states are members of the WTO.140 They are generally
obliged to comply with the TRIPS Agreement.141 However, as stated
above, LDCs are exempt from applying some general provisions of the
TRIPS until 2021 and pharmaceutical related provisions until 2033.142
The possibility of utilizing the above transition periods to exclude
pharmaceuticals from patentability offers LDCs an opportunity to
develop a base for manufacturing generic pharmaceutical products.
The transition period has generally not been utilized, however, by
most LDCs within the SADC region. This is in contrast with their East
African counterparts, Uganda,143 Rwanda,144 and Burundi,145 who have
recently amended their legislation to take advantage of the transition
period and exclude pharmaceuticals from patent protection.146 Most
139. The Industrial Property Act (2014).
140. For
a
list
of
WTO
Members
see
https://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_e.htm.
141. TRIPS Agreement supra note 1, Article 1.
142. The Decision of the Council of the TRIPS of 6 November 2015.
143. Section 8 (3)(f) of the Uganda Industrial Property Act (2014).
144. Article 18 of the Rwanda Intellectual Property Act (2009).
145. Article 17 of the Burundi Industrial Property Act.
146. See Article 18 of the Rwandan Industrial Property Act, 2009, Article 17 of the
Burundi Industrial Property Act. Section 8(3)(f) of the Ugandan Industrial Property Act, 2014
reads:
The following shall not be regarded as inventions and shall be excluded from
patent protection—pharmaceutical products and test data until 1st January 2016
or such other period as may be granted to Uganda or least developed countries
by the Council responsible for administering the Agreement on trade related
aspects of intellectual property under the World Trade Organization.
Article 102 (15) of the Ugandan Act provides that
the rights accruing from patents for pharmaceutical processes shall not be
enforceable until January 1, 2016, or such other period as may be granted to
Uganda or least developed countries by the council responsible for administering
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SADC LDCs still maintain patent laws that they inherited from their
colonial masters.147 As a recent SADC commissioned study observed,
virtually all SADC countries have not taken advantage of the
pharmaceutical transition periods and “permit pharmaceutical
patenting.”148 The only exception is Zanzibar, part of Tanzania, which
has a separate law to exclude pharmaceuticals from patent
protection.149 Apart from prematurely according patent protection to
pharmaceutical products, these laws contain provisions that give more
protection to patent owners than required by the TRIPS Agreement.150
This is problematic given that transition periods were granted “in view
of the special needs and requirements of least-developed country
Members, their economic, financial and administrative constraints, and
their need for flexibility to create a viable technological base.”151
A number of reasons may be given as to why this is the case. First,
these countries believe that compliance with the TRIPS Agreement can
benefit them by creating incentives for innovation. Second, these
countries are advised by agencies, such as World Intellectual Property
Organization (WIPO) that strong patent regimes stimulate domestic
innovation. However, existing studies reveal that protection and
enforcement of patents stimulate local innovation “only if
accompanied by high levels of economic and infrastructural
development, educational attainment and economic freedom.”152 A
study by Margaret Kyle and Yi Qian also concludes that “the existence
of IPRs is neither necessary nor sufficient for the launch of

the agreement on trade related aspects of intellectual property under the WTO if
alternative processes for making pharmaceutical products that are not subject to
exclusive rights are not available and those patents, if enforced, indirectly give
rise to market exclusivity of the pharmaceutical products in question.
147. These include Malawi, Zambia, Swaziland, and Lesotho.
148. Sisule Musungu, Pharmaceutical Patents, TRIPS Flexibilities and Access to
Medicines in Southern African Development Community (SADC), Report for a SADC member
States Consultation (September 18, 2012).
149. Section 3(1) of the Zanzibar Industrial Property Act (2014)
150. For example, The Malawi Patents Act, Section 30 provides for the extension of patent
terms beyond the basic term provided for in Section 29. This extension obviously goes beyond
the requirements of the TRIPS Agreement. Section 30 exceeds the requirements of TRIPS
given that the Agreement does not oblige Members to extend patents beyond their basic term.
See Robert Lettington & Chikosa Banda, A Survey of Policy and Practice on the Use of Access
to
Medicines
Related
TRIPs
Flexibilities
in
Malawi,
DFID
(2004),
http://www.who.int/hiv/amds/countries/mwi_SurveyUseTRIPs.pdf. Additionally, the TRIPS
Agreement does not oblige LDCs to provide protection for patents . However, the SADC
countries as we have seen above maintain patent protection for pharmaceuticals.
151. TRIPS Agreement supra note 1, Article 66(1).
152. Qian Yi, Do National Patent Laws Stimulate Domestic Innovation in a Global
Patenting Environment?, 89 REV. ECON. & STATs. 436 (2007).
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pharmaceuticals at country level.”153 On the contrary, it might
adversely impact the freedom of manufacturers to make generic
versions of essential pharmaceuticals and to broaden their product
range.154 It is difficult to imagine how SADC LDCs can develop a
technological base if they prematurely comply with all the provisions
of the TRIPS Agreement. The premature implementation of the TRIPS
Agreement would stifle the development of useful products in LDCs
by preventing “reverse engineering” and by obstructing access to
research tools and platform technologies.155 This would, in turn,
hamper the ability of these LDCs to develop technological capacity,
including pharmaceutical R&D and production capacity.156
Nevertheless, most SADC countries have revised or have
embarked on the process of revising their IP laws to incorporate or
update TRIPS flexibilities. These include Malawi, Seychelles,157
Namibia,158 Zanzibar,159and Botswana.160 The progressive country level
legal reforms include incorporation of Article 31bis of the TRIPS
Agreement.161 Some LDCs are developing laws that exclude
153. Margaret Kyle & Yi Qian , Intellectual Property Rights and Access to Innovation:
Evidence from TRIPS, 23 NAT’L BUREAU OF ECON. RESEARCH, WORKING PAPER NO. 20799
(2013).
154. Syam, supra note 2, at 6.
155. Innovation in the Least Developed Countries: Going Beyond Intellectual Property
Rights, LDC Report Highlights-Based on the Least Developed Countries Report, UNCTD, 2
(2007), http://unctad.org/en/docs/ldcrh2_en.pdf.
156. Id.
157. Seychelles Industrial Property Act (2014).
158. NAMIBIA INDUSTRIAL PROPERTY ACT (2012).
159. ZANZIBAR INDUSTRIAL PROPERTY ACT (2014).
160. BOTSWANA INDUSTRIAL PROPERTY ACT (2010).
161. Section 31(1) of the Botswana Industrial Property Act (2010) authorizes the Minister
to issue compulsory licenses in the public interest. Section 31(3) of the Act, however, waives
the “domestic market” condition by providing as follows: The exploitation of the patented
invention under subsection 1shall be for the supply of the domestic market in Botswana only,
except where paragraph 1 or 3 of Article 31bis of the TRIPS Agreement applies. Section 32(2)
provides that “the importation of the patented product by a Government agency or any
authorized person shall be solely for public non-commercial use within Botswana, except
where paragraph 1 or 3 of Article 31bis of the TRIPS Agreement is applicable.” Similarly,
section 57(1)(e) of the Namibia Industrial Property Act (2012) also domesticates article 31bis
of the TRIPS Agreement. It provides that where a patent relates to a pharmaceutical product
in respect of which Namibia has insufficient or no manufacturing capacity as contemplated in
the decision of the General Council of the WTO of August 30, 2003 or in Article 31bis of the
TRIPS and a License for the importation of the patented product is required” the Minister may
issue a “compulsory license to exploit an invention including by importation. Section 14 of
the Zanzibar Industrial Property Act (2014) recognizes compulsory licensing for importation
pursuant to “the decision of the General Council of the WTO of 30th August 2003.” Section
97(3) of the Act states:
compulsory license shall be available for manufacture and export of patented
pharmaceutical products to any country having insufficient or no manufacturing
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pharmaceuticals from patentability. Zambia has a draft law which
purports to exclude pharmaceuticals from patentability until it
graduates from LDC status.162 Zanzibar has a similar provision in its
law.163 Consequently, SADC countries are adopting legal provisions
aimed at taking advantage of the 30 August waiver to facilitate the
importation of drugs from countries that have generic production
capacities. The legal provisions are also designed to facilitate the
production for export and importation for re-export of medicines
within the region.164 South Africa is in the process of reviewing its
patent policy.165 Failure to accelerate the implementation of TRIPS
flexibilities may be symptomatic of the fact that SADC countries do
not consider implementing TRIPS flexibilities as a human rights
obligation. Conversely, the African Union Resolution 141 on Access
to Health and Needed Medicines in Africa calls upon states to take
measures to promote, protect, and fulfill access to medicines.166
Specifically, the Resolution recognizes access to pharmaceuticals as
an indispensable element of the right to a highest attainable standard
of health.167 Accordingly, it urges states to promote access to
pharmaceuticals by avoiding measures that negatively impact access.
These include “implementing intellectual property policies that do not
take advantage of all the flexibilities in the . . . TRIPS Agreement that
promote access to affordable medicines.”168 Failure by states to
appreciate the human rights basis of their obligations may explain their
capacity in the pharmaceutical sector for the concerned product to address public
health problems or needs, provided compulsory license or authorized use of the
patent has been granted by such country.
162. Section 16 of the Zambian Patents Bill (2010) provides as follows:
Pharmaceutical products and processes shall not be patentable until 1 January
2016 or until the expiry of such later period of extension as may be agreed upon
by the World Trade Organization for least developed countries.” Section 68(3)
empowers the Registrar promptly to “reject all pharmaceutical and medicines
related micro-biological patents until 1 January 2016 or until the expiry of such
later period of extension as may be agreed upon by the World Trade Organization
for least developed countries.
163. Section 3(1) of the Zanzibar Industrial Property Act (2014) excludes pharmaceutical
products and processes from patent protection “until January 1, 2016 or the expiry of such
later period of extension as agreed upon by the WTO Council for the TRIPS.”
164. In order to take advantage of the 30 August waiver.
165. The Policy partly aims at promoting access to essential medicines. See DEP’T OF
TRADE AND INDUSTRY, DRAFT NATIONAL POLICY ON INTELLECTUAL PROPERTY, 5 (2013),
http://ip-unit.org/wp-content/uploads/2013/09/DRAFT-IP-POLICY.pdf.
166. Resolution on Access to Health and Needed Medicines in Africa, The African
Commission on Human and People’s Rights, Meeting of its 44th Ordinary Session held in
Abuja
Nigeria,
AU
RESOLUTION
141,
10–24
(September
2005),
http://www.achpr.org/sessions/44th/resolutions/141/.
167. Preamble of the resolution.
168. Paragraph 1.
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laxity in domesticating TRIPS flexibilities.
V. CHALLENGES
One of the major challenges to implementing TRIPS flexibilities
in the SADC region is policy incoherence. A good number of SADC
LDCs still provide patent protection for pharmaceuticals despite the
fact that they are not obliged to do so under the TRIPS Agreement.
This is because LDCs view IP as a vital tool for achieving their
developmental objectives.169 The understanding may be attributable to
the technical assistance these countries receive from WIPO and other
development partners.170
While SADC member states are increasingly incorporating
TRIPS flexibilities in national legislation, the actual usage of these
flexibilities still remains limited.171 This is partly attributed to a number
of factors, including inadequate capacity in the region to implement
these flexibilities in practice, inadequate awareness of the flexibilities,
and pressure from developed countries against the use of
flexibilities.172 The impact of this is that SADC countries cannot take
full advantage of Article 31 bis which allows members to produce
pharmaceuticals for export to other members. Failure to incorporate or
utilize flexibilities also means that members cannot utilize the system
provided for under Article 31 bis to import medicine from outside the
region for re-exportation to other members within the SADC. In this
respect, SADC members appear to be motivated more by the desire to
protect their sovereignty than the need to solve common problems.
This has accordingly delayed the full implementation of the SADC
PBP.
Ten LDCs, five of which are SADC states, are ARIPO
members.173 ARIPO was created in 1976 by the Agreement on the
169. See submission by Sangeeta Shashikant and Gopakumar Kapoori to the UN Secretary
General’s High Level Panel on Access to Medicines, March 1, 2016,
http://www.unsgaccessmeds.org/inbox/2016/3/1/third-world-networkc.
170. See submission by Sangeeta Shashikant and Gopakumar Kapoori to the UN Secretary
General’s High Level Panel on Access to Medicines, March 1, 2016,
http://www.unsgaccessmeds.org/inbox/2016/3/1/third-world-networkc.
171. See Sisule Musungu, Pharmaceutical Patents, TRIPS Flexibilities and Access to
Medicines in Southern African Development Community (SADC), REPORT FOR A SADC
MEMBER STATES CONSULTATION, (September 18, 2012)..
172. See, e.g., UNAIDs, Intellectual Property and Access to Health Technologies (2016),
http://www.unaids.org/sites/default/files/media_asset/JC2820_en.pdf.
173. Lusaka Agreement on the Creation of the African Regional Organization on
Intellectual
Property
Rights
(ARIPO)
(1976),
http://www.wipo.int/edocs/lexdocs/treaties/en/ap001/trt_ap001_001en.pdf.
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Creation of the African Regional Industrial Property Organization
adopted at Lusaka, in Zambia.174 The objectives of ARIPO include
promoting the harmonization and development of the industrial
property laws among member states. ARIPO also aims at
strengthening “cooperation between states in respect of protection and
exploitation of patents.”175 The following SADC countries are
members of ARIPO: Botswana, Lesotho, Malawi, Mozambique,
Namibia, Swaziland, Tanzania, Zambia, and Zimbabwe.
The ARIPO Secretariat is responsible for granting patents on
behalf of member states under the Harare Protocol on Patents and
Industrial Designs. The Secretariat undertakes formal and substantive
examinations of patent applications to ensure compliance with the
prescribed formal requirements and substantive criteria for
patentability.176 When a patent is granted by ARIPO, designated states
are supposed to be notified and given a chance to reject the patent.177
A designated state is given six months to communicate in writing to
ARIPO that the granted patent shall have no effect in its territory. The
Harare Protocol makes available to states two grounds for rejecting
ARIPO granted patents: first, that the invention is not patentable under
the provisions of the protocol, and second, that “because of the nature
of the invention, a patent cannot be registered or has no effect under
the” state’s national law.178 Failure by the designated state to respond
to a notification within six months renders the patent effective in its
territory.179
One major drawback of the Harare Protocol is that it does not
recognize LDC transition periods, granted under Article 66 of the
TRIPS Agreement and extensions thereof.180 As a result, it is not
uncommon for ARIPO to grant pharmaceutical patents in which LDCS
are designated. This is worrisome considering that most members of
ARIPO are LDCs and maintain patent laws that do not exclude
pharmaceuticals from patentability. In fact, existing studies reveal that
rejection of ARIPO patents is uncommon. Most LDCs routinely accept
pharmaceutical patents granted by ARIPO partly because of lapses in

174. Agreement on the Creation of the African Regional Industrial Property Organization.
175. See the Preamble to the Harare Protocol on Patents and Industrial Designs within the
Framework of the African Regional Intellectual Property Organization.
176. Section 3 (2)(a) and section 3(3) of the Harare Protocol.
177. Section 3(6) of the Harare Protocol.
178. Section 3(6) of the Harare Protocol.
179. Section 3(7) of the Harare Protocol.
180. Syam, supra note 2, at 8.
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the notification and objection systems.181 As Robert Lewis-Lettington
and Chikosa Banda have observed, this “means that ARIPO standards
are de facto emerging as a uniform regional standard that may, in the
future, need to be examined in its own right.”182
Given the implications of the ARIPO system for the use of
transition periods and other flexibilities, it is high time the ARIPO
system be thoroughly scrutinized. In this context, commentators have
recommended that “the Harare Protocol should exempt the territory of
LDCs from the grant of pharmaceutical patents.”183 This would not be
a farfetched idea. The Organisation Africaine de la Propriété
Intellectuelle (OAPI), which is ARIPO’s counterpart in francophone
Africa, has amended its treaty to provide for the non-applicability of
pharmaceutical patents to LDCs. Article 46 of the OAPI agreement
provides that
Member States that are LDCs are not obliged to
implement the provisions of Annex 1 regarding patents
consisting of, or related to, a pharmaceutical product,
nor to implement the provisions of Annex VIII
regarding confidential information, until 2033 or on the
date on which they stop to be classified as an LDC.184
Incorporating a provision similar to the terms above, into the
Harare Protocol, would ensure coherence between regional and the
progressive patent law reforms that are taking place in LDCs.
Without addressing the above policy contradictions, it will be
difficult for SADC members to make progress in safeguarding access
to medicines and stimulating local/regional production of
pharmaceuticals.
VI. CONCLUSION
The adoption of the SADC PBP and the increasing incorporation
of TRIPS flexibilities in the domestic laws present a vital window of
opportunity for member states to take advantage of TRIPS flexibilities
181. Sisule Musungu, Access to ART and other Essential Medicines in Sub-Saharan
Africa:
Intellectual
Property
and
Relevant
Legislation
(2007),
http:
apps.who.int/medicinedocs/documents/s18248en/s18248en.pdf; Lettington & Banda, supra
note 150, at 33; Shashikant, supra note 49.
182. Lettington & Banda, supra note 150, at 33.
183. Shashikant, supra note 49, at x.
184. Organisation Africaine de la Propri. . .t. . . Intellectuelle (OAPI), Article 46. (1977),
http://www.oapi.int/index.php/fr/oapi/cadre-juridique/accord-de-bangui.
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and waivers in order to promote local/regional production of
pharmaceuticals. A number of challenges and barriers need to be
surmounted, however, in order to make local and regional production
a reality. First, SADC countries have been over-dependent on India as
a source of generic pharmaceuticals and have given inadequate
attention to the implication of post-2005 Indian law and policy reforms
on future access to medicine. This has obviated the need to develop
local and regional production capacity and reform domestic legislation
in order to support local production. Second, the SADC PBP is not
legally binding. Hence, Members have the option of whether to
implement it or not. Third, SADC members have, historically, had
limited expertise in IP law. This has undermined progress in law
reform.
Recent developments in the SADC region suggest, however, that
countries are increasingly becoming aware of the need to find
sustainable solutions to the problem of how to access pharmaceutical
products. Consequently, they have initiated law patent law reform
processes that seek to take full advantage of flexibilities, including the
transition periods, in order to stimulate local and regional production
of pharmaceuticals.
While this is a welcome development, the pace at which SADC
LDCs are reforming their laws is worrisome. This is evidenced by the
fact that only one SADC LDC has, to date, enacted a law that takes
advantage of the transition periods. As noted above, there are a number
of factors behind this, which include inadequate in-country technical
and technological capacity, inappropriate TRIPS-related technical
assistance programs, and pressure from developed countries.
A number of concrete steps can be taken to accelerate the pace at
which SADC countries are adopting flexibilities. First, the SADC
should amend its Protocols on Health and Trade185 in order to
incorporate TRIPS-related access to medicines provisions. These
provisions should oblige all Member States to domesticate flexibilities
and LDCs to take advantage of the TRIPS pharmaceutical waiver. This
would pave way for the prioritization of these issues in national legal
and policy frameworks. SADC can also take advantage that the
majority of its members are LDCs and take advantage of the Article 31
bis to facilitate local/regional production of pharmaceuticals.
Incorporating the foregoing provisions into a legally binding protocol
would accelerate their adoption by Members. Second, the SADC
185. Southern African Development Community (SADC) Protocol on Trade (1996).
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should recognize that access to essential medicines is a human right.
Accordingly, individual Members have an obligation to go beyond
rhetoric and take concrete steps towards the progressive realization of
this right. One strategy towards this would be to popularize the
implementation of African Union Resolution 141, which calls upon
states to promote, implement, and fulfill access to medicines by
adopting TRIPS flexibilities and taking advantage of the TRIPS
waivers. Third, there is an urgent need for financial and technical
assistance to enable Members to incorporate TRIPS flexibilities. Much
of the progress that SADC Members have registered to date has come
from the technical support rendered by the Southern African Regional
Program on Access to Medicines and Diagnostics (SARPAM). This
program has since expired, and it is imperative that new regional
vehicles of technical assistance be established to complete the work
that SARPAM started. Moreover, Article 67 of the TRIPS Agreement
opens up a window of opportunity for SADC Members to request for
and receive technical assistance from developed countries. It obliges
developed countries to “provide technical and financial cooperation in
favor of developing and least-developed country Members.”186 The
cooperation envisaged by this provision includes “assistance in the
preparation of laws and regulations on the protection and enforcement
of intellectual property rights.”187 The TRIPS Agreement, thus,
contains inbuilt mechanisms to facilitate the acceleration of the
implementation of its provisions, including its flexibilities and
waivers. The pace at which reforms will take place will largely depend
on the performance of the above obligations by developed and
developing states, including LDCs. Given that the implementation of
the TRIPS flexibilities is undermined by inadequate expertise, it would
be useful to provide post-reform technical support to LDCs. LDCs
would require support in order to effectively implement TRIPS
flexibilities and waivers in practice.188
However, it would be difficult to promote the incorporation of
TRIPS flexibilities and the adoption of TRIPs waivers unless SADC
countries see the direct relevance of the flexibilities to their respective
countries. At present, most SADC LDCs do not see the direct
implications of failure to incorporate TRIPS flexibilities for access to
newer pharmaceuticals. This is because they have no viable
technological base and are heavily dependent on India for their
pharmaceutical needs. As Médecins Sans Frontières (MSF) observes,
186. TRIPS Agreement supra note 1, at Section 67.
187. Id.
188. Lettington & Banda, supra note 149, at 41.
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“extending the period of TRIPS implementation is just one step in
addressing the unique challenges of LDCs in Africa but above all there
is need to address the underlying issues beyond extensions such as
helping LDCs build their technological base.”189
Consequently, a viable manufacturing base cannot be created
without external support. Developed countries have an obligation
under Article 66(1) of the TRIPS Agreement to encourage LDCs to
create a good and viable technological base. This would be by
provision of incentives to enterprises and institutions in their territories
for the purpose of promoting and encouraging technology transfer to
LDC members. Developed countries must also help SADC generic
manufacturers to develop the capacity to produce pharmaceuticals that
meet WHO prequalification standards. Given the limited nature of the
market in individual states, this would help create a regional and donor
market for such pharmaceuticals.
SADC Members need to understand the important role
local/regional production of pharmaceuticals can play in addressing
the gap left by changes in the Indian IP landscape. They also need to
understand the potential utility of flexibilities and waivers as tools for
the development of a viable technological base to support generic
production. In short, the domestication of TRIPS flexibilities would
only be accelerated if LDC members appreciate tangible benefits of
doing so.

189. MSF, supra note 37, at 16.

